Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Expenses (2024 - 2025)

Silence Therapeutics' Operating Expenses history spans 2 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 32.62% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $28.3 million, up 15.53%, while the annual FY2025 figure was $68.5 million, 154.86% up from the prior year.
  • Operating Expenses for Q4 2025 was $3.7 million at Silence Therapeutics, down from $5.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $18.7 million in Q2 2025 and bottomed at -$3.5 million in Q1 2024.